Dhiraj D Bhatia

Dec 9, 2024 | biorxiv.org | Payal Vaswani |Krupa Kansara |Ashutosh Kumar |Dhiraj D Bhatia

AbstractParkinsons disease is one of the neuropathies characterized by accumulation of alpha-synuclein protein, leading to motor dysfunction. Levodopa is the gold standard treatment, however, in long term usage, it leads to levodopa induced dyskinesia (LID). New therapeutic options are need of the hour to treat the alpha-synuclein based neuropathies. The role of imbalance of neurotransmitters other than dopamine has been underestimated in alpha-synuclein based neuropathies.

Jul 4, 2024 | biorxiv.org | Payal Vaswani |Dhiraj D Bhatia

AbstractCancer is a complex disease, with multiple treatment modalities, but no definitive cure. The tumor microenvironment contributes to the complexity of the disease by forming a niche of multiple cell types supporting each other to carry out various cellular functions. Tumor associated macrophages are one such kind of cells which support the tumor microenvironment via immunosuppression. DNA tetrahedron (TD), a widely explored DNA nanocage, has shown a lot of potential in therapeutics.

May 30, 2024 | biorxiv.org | Nihal Singh |Ankur Singh |Dhiraj D Bhatia

AbstractDifferent modalities of DNA-Collagen complexes have been utilized primarily for gene delivery studies. However, very few studies have investigated the potential of these complexes as bioactive scaffolds. Further, no studies have characterized the DNA-Collagen complex formed from the interaction of self-assembled DNA macrostructure and collagen.